4263 Stock Overview
Develops and sells therapeutic applications in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SUSMED,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥619.00 |
| 52 Week High | JP¥1,412.00 |
| 52 Week Low | JP¥375.00 |
| Beta | 1.5 |
| 11 Month Change | 9.95% |
| 3 Month Change | 21.37% |
| 1 Year Change | -55.31% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4263 | JP Healthcare Services | JP Market | |
|---|---|---|---|
| 7D | 7.7% | 8.6% | -0.5% |
| 1Y | -55.3% | -30.1% | 10.8% |
Return vs Industry: 4263 underperformed the JP Healthcare Services industry which returned -30.1% over the past year.
Return vs Market: 4263 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4263 volatility | |
|---|---|
| 4263 Average Weekly Movement | 7.9% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4263's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4263's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 39 | Taro Ueno | www.susmed.co.jp |
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease.
SUSMED,Inc. Fundamentals Summary
| 4263 fundamental statistics | |
|---|---|
| Market cap | JP¥10.37b |
| Earnings (TTM) | -JP¥374.00m |
| Revenue (TTM) | JP¥342.00m |
30.3x
P/S Ratio-27.7x
P/E RatioIs 4263 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4263 income statement (TTM) | |
|---|---|
| Revenue | JP¥342.00m |
| Cost of Revenue | JP¥10.00m |
| Gross Profit | JP¥332.00m |
| Other Expenses | JP¥706.00m |
| Earnings | -JP¥374.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.32 |
| Gross Margin | 97.08% |
| Net Profit Margin | -109.36% |
| Debt/Equity Ratio | 0% |
How did 4263 perform over the long term?
See historical performance and comparison